Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2 study of belantamab alone or with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma
MOH_2026-05-16_015822Phase 2Recruiting
- Sponsor
- GSK
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belantamab, belantamab mafodotin, pomalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by GSK. Primary endpoints: Safety and tolerability and Clinical activity. Started May 2026; status: recruiting.
02
Drugs
belantamabbelantamab mafodotinpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2026-05-16_015822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-16_015822.